Eli Lilly grew revenue 39% even after cutting GLP-1 prices 15%
As seen on the 24/7 Wall St. homepage on October 31, 2026.
Lilly is absorbing lower GLP-1 pricing, with 53% more patients on its drugs funding a push into gene editing and oncology.
Eli Lilly cut its prices 15% and still sold $24.4B in three months, up 39%. How? 53% more people are taking its drugs. Its next weight loss shot took off about 28% of patients' body weight in trials. The weight loss money is now paying for gene editing, cancer drugs and cell https://t.co/eaqcVLBSEm [Quoted @ThierryBorgeat]: CEO of Eli Lilly $LLY The biggest beneficiary of AI is Biotech. The case: https://t.co/V2nfeWzPeh https://t.co/iyKmslKzcv https://t.co/3gvq5zfzdP
- Replies0
- Reposts0
- Likes0
Continue ReadingShow less
Eli Lilly posted $24.4 billion in quarterly revenue despite voluntarily cutting its drug prices, because far more patients are now taking its medicines and volume more than offset the price concession.
That volume surge is the core story for investors. A price cut that would ordinarily compress revenue instead became a demand catalyst, suggesting the addressable market for Lilly's GLP-1 drugs is still expanding rapidly rather than approaching saturation.
Sponsored
The next act in the weight-loss franchise is already in trials. Lilly's next-generation shot removed about 28% of patients' body weight in clinical testing, a result that, if it holds through approval, would meaningfully raise the bar for the entire obesity drug category.
The profits flowing in from weight-loss drugs are now being recycled into gene editing, cancer drugs, and cell therapies, according to the post. For investors tracking Lilly purely as a GLP-1 play, that pipeline diversification changes the longer-term risk profile of the stock considerably.
Mentioned: LLY